Global study aims to uncover best treatments for Immunotherapy-Linked heart condition
NCT ID NCT07633587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
ATROPOS is an international study collecting data from 1,500 cancer patients who developed heart inflammation (myocarditis) after receiving immune checkpoint inhibitors. Researchers will analyze how different immunosuppressive treatments, such as steroids, affect survival rates at 30, 90, and 360 days. The goal is to identify which treatment strategies are linked to better outcomes, helping guide future care for this serious side effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify which immunosuppressive treatments are linked to better survival in patients with this rare heart condition caused by cancer immunotherapy.
- What could go wrong
- This is an observational study, not a controlled trial, so it can show associations but not prove cause and effect. Results may be affected by unmeasured factors or differences in patient care across countries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Pitie-Salpetriere / CIC-2503
RECRUITINGParis, France